Results
1 -
6 of
6Ongoing Clinical Trials in Myeloproliferative Neoplasms, Myeloproliferative Neoplasms Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance, Oncogene Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application, Biomarker Research